Solventum (NYSE:SOLV) Announces Quarterly Earnings Results

Solventum (NYSE:SOLV) posted its earnings results on Thursday. The company reported $1.50 earnings per share for the quarter, topping analysts’ consensus estimates of $1.43 by $0.07, Zacks reports. Solventum had a return on equity of 31.62% and a net margin of 18.13%.The firm had revenue of $2.10 billion for the quarter, compared to the consensus estimate of $2.05 billion. During the same quarter in the prior year, the business earned $1.64 EPS. The business’s revenue for the quarter was up .7% on a year-over-year basis. Solventum updated its FY 2025 guidance to 5.980-6.080 EPS.

Solventum Stock Up 7.8%

Shares of NYSE:SOLV traded up $5.20 during trading on Friday, reaching $71.48. 1,739,249 shares of the stock traded hands, compared to its average volume of 915,290. The stock has a market cap of $12.39 billion, a P/E ratio of 8.24, a price-to-earnings-growth ratio of 2.69 and a beta of 0.48. The company has a debt-to-equity ratio of 2.14, a quick ratio of 0.86 and a current ratio of 1.22. The stock has a 50-day moving average of $71.97 and a two-hundred day moving average of $72.39. Solventum has a 52-week low of $60.70 and a 52-week high of $85.92.

Institutional Trading of Solventum

Several institutional investors have recently added to or reduced their stakes in SOLV. CYBER HORNET ETFs LLC purchased a new position in shares of Solventum in the second quarter worth $28,000. MUFG Securities EMEA plc bought a new stake in Solventum in the 2nd quarter worth about $31,000. State of Wyoming purchased a new position in Solventum in the 2nd quarter worth about $33,000. B. Riley Wealth Advisors Inc. purchased a new position in Solventum in the 2nd quarter worth about $233,000. Finally, United Services Automobile Association bought a new position in Solventum during the 1st quarter valued at about $239,000.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. Wall Street Zen lowered Solventum from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, September 9th. Morgan Stanley upgraded shares of Solventum from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $80.00 to $103.00 in a report on Tuesday, July 15th. UBS Group initiated coverage on shares of Solventum in a research note on Wednesday, October 1st. They issued a “neutral” rating and a $77.00 price target for the company. Piper Sandler boosted their price objective on shares of Solventum from $94.00 to $98.00 and gave the stock an “overweight” rating in a research note on Friday. Finally, Zacks Research raised shares of Solventum from a “hold” rating to a “strong-buy” rating in a research note on Monday, September 15th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $85.33.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.